Redeye takes a positive stance towards Fortnox following a solid Q3 report, with strong net customer...
Redeye retains its positive view of Carasent following the Q3 report.
- Q3 trading update and reiterated FY guidance... - .
- OEM and AM challenges to normalise in Q1'25e - '24e-'26e EBIT down 18-3%; 20% CAGR '23-'26e - 30-1...
- ~40% y-o-y order intake growth in Q3 provides visibility - Minor positive estimate revisions - NTM...
- Cyclical, variable volumes behind miss & soft near-term outlook - We cut '25e and '26e adj.
- Q3 EBITA 3% above IR consensus, 5% above ABGSCe - Focus on continued strong trend in Medical Solut...
- Slower recovery, but positive gross margin trend - We lower '24e-'26e adj.
- Adj. EBIT better but OCF down in Q3 - Transition in progress - Adj.
- Minor estimate changes - Solid profitability ahead as growth conditions stall - EV/ARR 1.
Förvaltningsresultat ökade i perioden med 21% drivet av förvärvet av grannfastigheten i Poznan i jun...
Redeye sees another quarter where AroCell delivers sales relatively in line with our estimates and c...
Tredje kvartalet 2024 uppvisade en något svagare omsättningstillväxt än vi räknat med och vi har val...
Dovre’s EUR 2.4m EBIT was soft relative to our estimate despite the high top line, but in our view v...
Consti's net sales in Q3 amounted to EUR 86.0m, slightly above our estimates (Evli est.
Vaisala’s Q3 fell short of our estimates for both net sales and profitability.
LapWall revised its 2024 financial guidance range yesterday, the positive update in terms of profita...
Redeye retains its positive view of Avensia following a solid Q3 report with a healthy underlying ma...
- FY sales SEK 2.1-2.2bn (prev. 2.4bn), EBITA margin 6% (prev.
- Q3 sales -6% below our ests. at SEK 202m, for -8% org.